In many studies, beta-blockers have been shown to decrease sudden cardiac death (SCD) in heart failure patients; other studies reported mixed results. Recently, several large randomized control ...trials of beta blockers have been carried out. It became necessary to conduct a systematic review to provide an up-to-date synthesis of available data.
We conducted a meta-analysis of all randomized controlled trials examining the use of beta-blockers vs. placebo/control for the prevention of SCD in heart failure patients. We identified 30 trials, which randomized 24,779 patients to beta-blocker or placebo/control. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Eligible studies had to be randomized controlled trials and provide information on the incidence of sudden cardiac death in heart failure patients. Additional inclusion criteria included: treatment for >30 days and follow-up≥3 months. Studies of patients<18 years, randomization to beta-blocker vs. an angiotensin converting enzyme (without placebo) and/or beta-blocker in both arms were excluded from the analysis. Pre-specified outcomes of interest included SCD, cardiovascular death (CVD), and all-cause mortality and were analyzed according to intention-to-treat.
We found that beta-blockers are effective in the prevention of SCD OR 0.69; 95% CI, 0.62-0.77, P<0.00001, cardiovascular death (CVD) OR 0.71; 95% CI, 0.64-0.79, P<0.00001, and all-cause mortality OR 0.67; 95% CI, 0.59-0.76, P<0.00001. Based on the study analysis, 43 patients must be treated with a beta-blocker to prevent one SCD, 26 patients to prevent one CVD and 21 patients to prevent all-cause mortality in one year.
Beta-blockers reduce the risk of sudden cardiac death (SCD) by 31%, cardiovascular death (CVD) by 29% and all-cause mortality by 33%. These results confirm the mortality benefits of these drugs and they should be recommended to all patients similar to those included in the trials.
Les photodermatoses Pillon, François
Actualités pharmaceutiques,
June 2016, 2016-06-00, Letnik:
55, Številka:
557
Journal Article
Recenzirano
Les photodermatoses sont des lésions dermatologiques induites par les différents types de rayon ultraviolets qui peuvent survenir sur des terrains génétiquement prédisposés ou être acquises suite à ...des phototraumatismes. En période estivale, le pharmacien d’officine est souvent consulté en première intention. Son rôle est notamment de conseiller une photoprotection efficace.
Photodermatoses are skin disorders caused by exposure to different types of ultraviolet rays which can occur in genetically predisposed individuals or be acquired following a phototrauma. In summer, the patient will often consult a pharmacist in the first instance. The pharmacist's role is notably to recommend effective sunscreen.
What is chicken pox? Foucher, Gérard; Pillon, François
Actualités pharmaceutiques,
November 2019, 2019-11-00, Letnik:
58, Številka:
590
Journal Article
What is bronchiolitis? Foucher, Gérard; Pillon, François
Actualités pharmaceutiques,
November 2018, 2018-11-00, Letnik:
57, Številka:
580
Journal Article
What is acute bronchitis? Foucher, Gérard; Pillon, François
Actualités pharmaceutiques,
September 2018, 2018-09-00, Letnik:
57, Številka:
578
Journal Article
PDF
